Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Sammson gene causes melanoma

In collaboration with big N2N researchers from UGent, VIB scientists from KU Leuven have revealed a remarkable link between malignant melanoma and…


Skin on skin: Melanoma research at VIB

Melanoma is a particularly nasty type of skin cancer. It progresses and spreads very quickly, and in many cases it is resistant to chemotherapy. C…


Preventing cervical cancer: vaccinating or freezing?

The group of human papillomaviruses has over 100 types, of which at least thirteen can cause cancer. The virus is present in people all over the w…

POPULAR TAGS

Researchers identify phosphorylation process vital to cancer growth

Written by DS on in the category news with the tags , .


Scientists at VIB-KU Leuven have identified a new mechanism that impacts tumor growth. The typical lack of oxygen in tumors doesn’t only stimulate proliferation, but also offsets the important role of the protein PHD2 as ‘cancer cell killer’. A possible solution lies in blocking the enzyme PP2A/B55, which restores the function of PHD2 and consequently slows down cancer growth. The research, led by Massimiliano Mazzone (VIB-KU Leuven), is published in the leading scientific journal Cell Reports.

Poor prognosis in cancer is typically correlated with hypoxia, a disturbance in the oxygen supply to the tumor cells. The protein PHD2 is known as a ‘hypoxic sensor’, as its function is highly dependent on the amount of oxygen. In the VIB-KU Leuven Center for Cancer Biology, Giusy Di Conza and colleagues, led by Massimiliano Mazzone, focused on the phosphorylation – the addition of a phosphate group – of this protein.

Interfering in phosphorylation process

When phosphorylated, PHD2 is more active, promoting the death of cancer cells in the low-oxygen areas of the tumor. However, tumors tend to overexpress the phosphatase PP2A/B55, an enzyme that removes the phosphate group (‘dephosphorylation’) from PHD2. As a result, PHD2 is partially inactivated, which offsets the positive effects of this ‘cancer cell killer’.

Prof. Massimiliano Mazzone (VIB-KU Leuven): “Surprisingly, we found that the phosphorylation status of PHD2 is regulated by pathways such as mTOR, which in tumor and normal cells represents the main sensor of metabolic stresses such as lack of nutrients or growth factors. This means that our findings might be applied not only to cancer but also to other diseases, such inflammatory or metabolic diseases.”

Phosphatase as a cancer target

During the research, Mazzone’s lab collaborated closely with several domestic and foreign researchers. In particular, the German ISAS lab (Dortmund) and the Leuven University Hospital played decisive roles, with the latter providing the human cancer samples necessary for the research. In these samples, the researchers discovered high expressions of PP2A/B55 in tumors compared to healthy tissues.

Mazzone: “This leads us to the conclusion that PP2A/B55 is a promising potential target for cancer therapy. That is why we started working together with an interested partner to study the potential of specific drugs against PP2A/B55. The ultimate goal is to design molecules that block the function of this phosphatase, thereby fighting cancer in a targeted way.”

Assessing the effects of future drugs

On top of new cancer treatment perspectives, these findings may also lead to new biomarkers: the phosphorylation status of PHD2 might be instrumental to understanding a tumor’s transformation process and, consequently, to select the appropriate treatment.

Mazzone: “To fully understand all the ins and outs of these processes, we also need to take a closer look at the tumor microenvironment and the immune system. After all, they strongly impact tumor growth. As we speak, we are defining the role of PP2A/B55 in both the tumor microenvironment and in immune cells. In this way, we hope to assess the effects of future drugs that inhibit PP2A/B55.”

Read more about: , .

RELATED ARTICLES
Sammson gene causes melanoma

In collaboration with big N2N researchers from UGent, VIB scientists from KU Leuven have revealed a remarkable link between malignant melanoma and…


Skin on skin: Melanoma research at VIB

Melanoma is a particularly nasty type of skin cancer. It progresses and spreads very quickly, and in many cases it is resistant to chemotherapy. C…


Preventing cervical cancer: vaccinating or freezing?

The group of human papillomaviruses has over 100 types, of which at least thirteen can cause cancer. The virus is present in people all over the w…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin V-Bio Ventures KU Leuven XpandInnovation Turnstone GSK UGent Flanders.bio Itera Life Science Janssen

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.